Company: CRL
Filing Date: 2025-02-19
Form Type: 10-K
Source: 0001100682-25-000011
Chunk: 155

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-02-19
Form: 10-K
Item: Item 8
Chunk 155
---
 and Development Lab) footprint, and offers incremental opportunities to partner with an emerging client base, many of which are engaged in cell and gene therapy development. The purchase price of Explora BioLabs was $284.5 million, net of $6.6 million in cash. The acquisition was funded through proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s RMS reportable segment. The Company incurred transaction and integration costs in connection with the acquisition of $2.9 million, and $7.5 million during fiscal years 2023 and 2022, respectively, which was primarily included in Selling, general and administrative expenses within the consolidated statements of income.

73

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Purchase price informationThe purchase price allocation for acquisitions during fiscal years 2024, 2023, and 2022 was as follows:Noveprim GroupSAMDI Tech, Inc.Explora BioLabsNovember 30, 2023January 27, 2023April 5, 2022(in thousands)Trade receivables$1,308 $513 $7,679 Inventories66,500 — — Other current assets (excluding cash)3,261 75 1,067 Property, plant and equipment36,154 593 37,369 Operating lease right-of-use asset, net104 — 48,613 Goodwill (1)190,024 37,129 215,752 Definite-lived intangible assets9,500 33,070 70,100 Other long-term assets (2)167,907 6 556 Deferred revenue— (43)(3,507)Other current liabilities (16,268)(351)(15,507)Operating lease right-of-use liabilities (Long-term)(97)— (57,193)Deferred tax liabilities(12,984)(8,191)(18,601)Other long-term liabilities(7,579)— (1,807)Redeemable noncontrolling interest (3)(45,426)— — Total purchase price allocation$392,404 $62,801 $284,521 (1) The goodwill resulting from these transactions is primarily attributable to the potential growth of the Company’s segments from new customers introduced to the acquired businesses or synergies to be realized from acquiring an internal supplier